Reported 1 day ago
Bank of America Securities has increased its price target for Metsera, Inc. (NASDAQ:MTSR) from $45 to $50, while keeping a Buy rating after the company reported positive developments in its obesity drug pipeline. Metsera's lead drug, MET-097i, has shown promising results in Phase 2b trials, with more data expected in September. The company is also making strides with another drug, MET-233i, and oral peptide programs, indicating potential growth in the coming years.
Source: YAHOO